Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Nursing Ethical Principles II

Nursing Ethical Principles II

Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pancreatic resection for metastatic renal cell carcinoma: outcomes in the era of immunotherapy and targeted therapy.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026

Same author

The Oncology Research Information Exchange Network (ORIEN) - Building a Real-World Collaborative, Patient-driven Infrastructure for Discovery Research and Precision Oncology.

Research square·2026

Same author

Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules.

Clinical genitourinary cancer·2026

Same author

Whole-proteome phage immunoprecipitation sequencing reveals germ cell tumor-specific immunosignature.

Nature communications·2026

Same author

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Journal for immunotherapy of cancer·2026

Same author

Determinants of pancreatic tropism in metastatic renal cell carcinoma.

JCI insight·2026

Search research articles

Related Experiment Video

Updated: Jul 2, 2025

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography

Published on: June 21, 2024

NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.

Robert J Motzer¹, Eric Jonasch², Neeraj Agarwal³

¹1Memorial Sloan Kettering Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN

|February 23, 2024

Summary

This summary is machine-generated.

The NCCN Guidelines for Kidney Cancer (Version 2.2024) offer updated recommendations for advanced renal cell carcinoma (RCC) systemic therapy. These insights highlight new clinical data for optimizing patient treatment strategies.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: Jul 2, 2025

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography

Published on: June 21, 2024

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Area of Science:

Oncology
Clinical Guidelines

Background:

Renal cell carcinoma (RCC) is a significant cancer diagnosis.
Effective management of advanced RCC relies on up-to-date treatment protocols.

Purpose of the Study:

To summarize key updates in systemic therapy for advanced renal cell carcinoma (RCC).
To present the NCCN panel's evaluation of new clinical data for Version 2.2024.

Main Methods:

Review of recent clinical trial data relevant to advanced RCC.
Expert panel evaluation and guideline formulation by the National Comprehensive Cancer Network (NCCN).

Main Results:

The NCCN Guidelines for Kidney Cancer (Version 2.2024) incorporate new systemic therapy options.
Updated recommendations reflect the latest evidence for advanced RCC treatment.

Conclusions:

The NCCN Guidelines provide essential, evidence-based recommendations for advanced RCC management.
Version 2.2024 ensures clinicians have access to current, multidisciplinary treatment strategies.